Literature DB >> 7542964

Transurethral laser ablation of the prostate--long-term results.

A J Costello1, D G Lusaya, H R Crowe.   

Abstract

Continuing experience with the use of Nd:YAG laser-fibre prostatectomy over the past 4 years has produced encouraging results. Of the 198 patients we treated with the 60-W/60-s technique, 74 were available for evaluation after undergoing laser ablation of the prostate between October 1990 and July 1994. In all, 29/74 and 9/74 patients were available for 24 and 36 months of follow-up, respectively. The American Urological Association (AUA) symptom scores, peak uroflow (Qmax) rates and post-void residual urinary volumes show marked improvement. Following laser ablation of the prostate (LAP), complications have included 16 patients with post-procedural recurrent obstructive symptoms requiring revision. Three patients developed urinary tract infection, two developed bladder-neck stenosis, four fully anticoagulated patients with clot retention required blood transfusion and three patients had epididymo-orchitis. The results show a sustained reduction in AUA symptom scores and maintained improvement in peak flow rates and residual volumes, with stabilization of the above-mentioned parameters occurring within 12-36 months. The results demonstrate the continued durability of the outcome of LAP.

Entities:  

Mesh:

Year:  1995        PMID: 7542964     DOI: 10.1007/bf00183627

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  13 in total

1.  Transurethral prostatectomy: practice aspects of the dominant operation in American urology.

Authors:  H L Holtgrewe; W K Mebust; J B Dowd; A T Cockett; P C Peters; C Proctor
Journal:  J Urol       Date:  1989-02       Impact factor: 7.450

2.  Cost-effectiveness of laser ablation of the prostate. Premature evaluation.

Authors:  T Jackson; A Street; A Costello; H Crowe
Journal:  Int J Technol Assess Health Care       Date:  1995       Impact factor: 2.188

Review 3.  Nonoperative management of benign prostatic hyperplasia.

Authors:  H Lepor
Journal:  J Urol       Date:  1989-06       Impact factor: 7.450

4.  A randomised single institution study comparing laser prostatectomy and transurethral resection of the prostate.

Authors:  A J Costello; H R Crowe; T Jackson; A Street
Journal:  Ann Acad Med Singapore       Date:  1995-09       Impact factor: 2.473

5.  Laser prostatectomy performed with a right angle firing neodymium:YAG laser fiber at 40 watts power setting.

Authors:  J N Kabalin
Journal:  J Urol       Date:  1993-07       Impact factor: 7.450

6.  Transrectal microwave hyperthermia for benign prostatic hyperplasia: long-term clinical, pathological and ultrastructural patterns.

Authors:  F Montorsi; L Galli; G Guazzoni; R Colombo; G Bulfamante; L Barbieri; V Matozzo; V Grazioli; P Rigatti
Journal:  J Urol       Date:  1992-08       Impact factor: 7.450

7.  High intensity focused ultrasound for the treatment of benign prostatic hyperplasia: early United States clinical experience.

Authors:  R Bihrle; R S Foster; N T Sanghvi; J P Donohue; P J Hood
Journal:  J Urol       Date:  1994-05       Impact factor: 7.450

8.  Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3,885 patients.

Authors:  W K Mebust; H L Holtgrewe; A T Cockett; P C Peters
Journal:  J Urol       Date:  1989-02       Impact factor: 7.450

9.  Sham versus transurethral microwave thermotherapy in patients with symptoms of benign prostatic bladder outflow obstruction.

Authors:  C W Ogden; P Reddy; H Johnson; J W Ramsay; S S Carter
Journal:  Lancet       Date:  1993-01-02       Impact factor: 79.321

10.  Further evaluation of transurethral laser ablation of the prostate in patients treated with anticoagulant therapy.

Authors:  T E Kingston; A K Nonnenmacher; H Crowe; A J Costello; A Street
Journal:  Aust N Z J Surg       Date:  1995-01
View more
  1 in total

1.  Laser prostatectomy: checkup on the promises.

Authors:  J Choi; E F Ikeguchi; A E Te; S A Kaplan
Journal:  Rev Urol       Date:  1999
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.